457 related articles for article (PubMed ID: 10809212)
1. Marrow toxicity of 33P-versus 32P-orthophosphate: implications for therapy of bone pain and bone metastases.
Goddu SM; Bishayee A; Bouchet LG; Bolch WE; Rao DV; Howell RW
J Nucl Med; 2000 May; 41(5):941-51. PubMed ID: 10809212
[TBL] [Abstract][Full Text] [Related]
2. Marrow-sparing effects of 117mSn(4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer.
Bishayee A; Rao DV; Srivastava SC; Bouchet LG; Bolch WE; Howell RW
J Nucl Med; 2000 Dec; 41(12):2043-50. PubMed ID: 11138691
[TBL] [Abstract][Full Text] [Related]
3. Biologic dosimetry of bone marrow: induction of micronuclei in reticulocytes after exposure to 32P and 90Y.
Lenarczyk M; Goddu SM; Rao DV; Howell RW
J Nucl Med; 2001 Jan; 42(1):162-9. PubMed ID: 11197968
[TBL] [Abstract][Full Text] [Related]
4. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions.
Bouchet LG; Bolch WE; Goddu SM; Howell RW; Rao DV
J Nucl Med; 2000 Apr; 41(4):682-7. PubMed ID: 10768569
[TBL] [Abstract][Full Text] [Related]
5. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
[TBL] [Abstract][Full Text] [Related]
6. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
[TBL] [Abstract][Full Text] [Related]
7. Biological dosimetry of bone marrow for incorporated yttrium-90.
Goddu SM; Howell RW; Giuliani DC; Rao DV
J Nucl Med; 1998 Mar; 39(3):547-52. PubMed ID: 9529309
[TBL] [Abstract][Full Text] [Related]
8. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
Nair N
J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
[TBL] [Abstract][Full Text] [Related]
9. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
10. S values for radionuclides localized within the skeleton.
Bouchet LG; Bolch WE; Howell RW; Rao DV
J Nucl Med; 2000 Jan; 41(1):189-212. PubMed ID: 10647623
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
[TBL] [Abstract][Full Text] [Related]
12. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
[TBL] [Abstract][Full Text] [Related]
13. Oligoradionuclidetherapy using radiolabelled antisense oligodeoxynucleotide phosphorothioates.
Kairemo KJ; Tenhunen M; Jekunen AP
Anticancer Drug Des; 1996 Sep; 11(6):439-49. PubMed ID: 8836109
[TBL] [Abstract][Full Text] [Related]
14. Bone pain palliation with 85Sr therapy.
Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
[TBL] [Abstract][Full Text] [Related]
15. A three-dimensional transport model for determining absorbed fractions of energy for electrons within trabecular bone.
Bouchet LG; Jokisch DW; Bolch WE
J Nucl Med; 1999 Nov; 40(11):1947-66. PubMed ID: 10565793
[TBL] [Abstract][Full Text] [Related]
16. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
[TBL] [Abstract][Full Text] [Related]
17. [Radioprotection and environmental pollution by the use of the radionuclides 89Sr, 186Re, and 153Sm for pain palliation in metastatic bone diseases. Related calculations].
Sbonias E
Hell J Nucl Med; 2005; 8(2):68-73. PubMed ID: 16142246
[TBL] [Abstract][Full Text] [Related]
18. Concerning the health effects of internally deposited radionuclides.
Raabe OG
Health Phys; 2010 Mar; 98(3):515-36. PubMed ID: 20147792
[TBL] [Abstract][Full Text] [Related]
19. A mouse bone marrow dosimetry model.
Muthuswamy MS; Roberson PL; Buchsbaum DJ
J Nucl Med; 1998 Jul; 39(7):1243-7. PubMed ID: 9669402
[TBL] [Abstract][Full Text] [Related]
20. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]